TILT Biotherapeutics
Prescription Drugs · Health Care
Overview
About TILT TILT Biotherapeutics is the world's leading company developing oncolytic immunotherapies to enable T-cell therapies for solid tumors. It is headquartered in Finland with a fully owned subsidiary in the United States.
Funding and backers
Total raised
$35.8M
2 rounds on record
Latest round
$25M
Series B · May 2025 · 17 mo ago
The money's age
Due for its next round
17 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | May 2025 | $25M | — | streetinsider.com |
| Venture round | Jan 2014 | $10.8M | — | en.ain.ua |
Registers and programsofficial lists and records that name the company
| Legal entity | TiltBio Inc | its site |
| Registered | 15 Apr 2013 |
Founders and leadersfrom filings, registers and the company's site
Gianfranco PittariChief Executive Officercompany's site
Miia KayeDirectorscompany's site
Finnish Industries InvestmentDirectorscompany's site
Julie Waras BrogrenDirectorscompany's site
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Learn how Dispatch Biotherapeutics is expanding the curative potential of immunotherapies by dispatching its Flare platform to overcome…
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
MediSix Therapeutics develops innovative T-cell therapies using its proprietary PEBL technology platform. An IASO Biotechnology subsidiary.
Azurity Pharmaceuticals is a privately held specialty pharmaceutical company that develops and markets medicines for patients underserved…
Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at…
Engrail delivers transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and…
People
Gianfranco Pittari
Chief Executive Officer
Miia Kaye
Directors
Finnish Industries Investment
Directors
Julie Waras Brogren
Directors
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
TILT Biotherapeutics Presents Encouraging Phase 1b Results in Ovarian Cancer at ESMO 2026
HELSINKI, Finland, Oct. 26, 2026 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing intravenousl...
Read more
Report
TILT Biotherapeutics Presents Encouraging Phase 1b Results in Ovarian Cancer at ESMO 2026
Four of nine evaluable patients responded to TILT-123 combined with pembrolizumab and pegylated liposomal doxorubicin, including two complete responsesHELSINKI, Finland, Oct. 26, 2026 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biote
Read more
Report
TILT Biotherapeutics Presents Encouraging Phase 1b Results in Ovarian Cancer at ESMO 2026
Four of nine evaluable patients responded to TILT-123 combined with pembrolizumab and pegylated liposomal doxorubicin, including two complete responses...
Read more
Report
TILT Biotherapeutics Ltd.
Research outputs, collaborations and relationships for TILT Biotherapeutics Ltd.
Read more
Report
TILT Biotherapeutics Provides Update on International Clinical Trial Progress with Intravenous Delivery Regimen for Cancer Immunotherapies
Data Presented at ESMO-IO supports the potential of personalized treatment strategies to improve clinical trial outcomesHELSINKI, Finland, Dec. 05, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing int
Read more
Report
TILT Biotherapeutics Presents Clinical Data on TILT-123 After Fully Intravenous Delivery Regimen at ESMO 2024
Results reinforce potential to develop TILT-123 as a systemic therapy in Phase II settingHELSINKI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it
Read more
Report
Report
TILT Biotherapeutics reports data from Phase I trial of ovarian cancer treatment
TILT Biotherapeutics has announced results from a Phase I clinical trial of TILT-123 alongside KEYTRUDA for ovarian cancer.
Read more
Report
Harnessing the Power of Oncolytic Viruses Pharmaceutical Technology
Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
2
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Helsinki
Finland
Regional office
Julie Waras Brogren
Biomedicum 2B, (2nd floor), 00290 Helsinki, Finland.
West Palm Beach
United States
Regional office
U.S. address
222 Lakeview Avenue Suite 800, West Palm Beach, FL 33401, USA